Optimizing and Personalizing interventions for schizophrenia Across the Lifespan (OPAL)

OPAL 中心以其为患有以下疾病的人优化和个性化干预措施的目标而命名 精神分裂症贯穿整个生命周期。该 ALACRITY 中心的目标人群是被诊断患有以下疾病的人 精神分裂症，通常影响从青春期或成年早期直至生命终结的个体。 受影响的个人通常有社会和职业功能受损；经验持久 精神病和情绪症状；存在可能进展的认知问题；并面临残疾风险 过早死亡。黑人、原住民和有色人种 (BIPOC) 个体尤其面临贫困风险 结果。此续订申请的目标是扩大我们的努力，加速开发和 在真实的临床环境中对精神分裂症实施有效的个体化治疗。 中心续展申请的具体目的如下： 1. 加强我们的基础设施，支持研究优化创新方法 对精神分裂症患者进行终生治疗，并加速临床转化 将精神分裂症研究纳入常规实践环境。 2. 开展开发、调整和测试创新、易于使用且以人为本的干预措施的项目 提高治疗参与度并且易于部署。 3. 培训科学家进行精神分裂症干预措施的转化研究。 OPAL 签名项目将使用医疗补助中心 16 年（2007 年至 2022 年）的数据和 医疗保险服务 (CMS) 将在诊断为痴呆症的人群中测试有关痴呆症危险因素的假设 精神分裂症并比较痴呆症诊断后治疗策略的有效性。我们随后将 整合我们的研究结果以适应提供评估和管理工具的认知健康工具包。 探索性项目 1 测试了一种新颖的、以人为本的评估和治疗启动方法 为社区心理健康诊所中患有精神病症状的 BIPOC 个人提供服务，其中包括 文化公式访谈的改编版本，以提高诊断和治疗的参与度。 探索性项目 2 将建立在欧洲所做的工作的基础上，以适应和测试可行性和 灵活自信社区治疗 (ACT) 的初步效果，这将使 ACT 团队能够 根据参与者的个人需求分配资源，提高效率和成果。 探索性项目 3 使用移动医疗 (mHealth) 技术提供基于测量的护理 并改善精神分裂症患者一生中以人为本的结果。 OPAL 项目使用中心的共同资源和方法来改进实施和 对重要问题进行个性化治疗。利益相关者帮助我们完善和调整干预措施 在现实环境中有效实施。

The OPAL Center is named after its goal of Optimizing and Personalizing interventions for people with schizophrenia Across the Lifespan. The target population for this ALACRITY Center is people diagnosed with schizophrenia, which typically affects individuals from adolescence or early adulthood until the end of life. Affected individuals commonly have impaired social and occupational functioning; experience persistent psychotic and mood symptoms; have cognitive problems that may progress; and are at risk for disability and premature death. Black, Indigenous, and People of Color (BIPOC) individuals are particularly at risk of poor outcomes. The goal of this renewal application is to extend our efforts to accelerate the development and implementation of effective, individualized treatments for schizophrenia in real clinical settings. The specific aims of the Center renewal application are as follows: 1. Strengthen our infrastructure that supports research that examines innovative ways to optimize treatments for people with schizophrenia throughout the lifespan and that accelerates the translation of clinical research on schizophrenia to routine practice settings. 2. Conduct projects that develop, adapt, and test innovative, accessible, and person-centered interventions that improve engagement in treatment and can be readily deployed. 3. Train scientists who will conduct translational research on interventions for schizophrenia. The OPAL Signature Project will use 16 years of data (2007-2022) from the Center for Medicaid and Medicare Services (CMS) to test hypotheses about risk factors for dementia among people diagnosed with schizophrenia and compare the effectiveness of treatment strategies after diagnosis of dementia. We will then integrate our findings to adapt a Cognitive Health Toolkit that provides assessment and management tools. Exploratory Project 1 tests a novel, person-centered approach to assessment and treatment initiation for BIPOC individuals with psychotic symptoms in community mental health clinics that incorporates an adapted version of the Cultural Formulation Interview to improve diagnosis and treatment engagement. Exploratory Project 2 will build on work done in Europe to adapt and test the feasibility and preliminary effectiveness of Flexible Assertive Community Treatment (ACT), which will allow ACT teams to allocate resources according to the individual needs of participants, improving efficiency and outcomes. Exploratory Project 3 uses mobile health (mHealth) technology to deliver measurement-based care and improve the person-centered outcomes of individuals with schizophrenia across the lifespan. OPAL projects use the Center's common resources and methodologies to improve implementation and personalization of treatments for important problems. Stakeholders help us to refine and adapt interventions for effective implementation in real-world settings.